Pfizer’s $1.5B cuts; Biogen’s $1.15B buyout; AstraZeneca’s $80B ambition; RNA startup merger; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Whether you will be in San Diego for BIO, we hope you will join us for our panels on some of the most important topics facing the industry right now, from China tensions to fixing gene therapy’s business model to the stop-start market recovery.

Pfizer’s $1.5B cuts

Months after beginning a $4 billion savings strategy, Pfizer is planning on a new $1.5 billion round of cost cuts, as well as what are likely to be more reductions in the future. The cuts include shrinking the company’s manufacturing base.

Biogen’s $1.15B buyout

Biogen struck…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks